Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...
Sarepta reported a patient death from acute liver failure after Elevidys treatment, though no new safety signal was identified. Over 800 patients have received Elevidys, and a recent CMV infection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback